BRPI0417509A - molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira - Google Patents

molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira

Info

Publication number
BRPI0417509A
BRPI0417509A BRPI0417509-3A BRPI0417509A BRPI0417509A BR PI0417509 A BRPI0417509 A BR PI0417509A BR PI0417509 A BRPI0417509 A BR PI0417509A BR PI0417509 A BRPI0417509 A BR PI0417509A
Authority
BR
Brazil
Prior art keywords
nucleic acid
hbc
recombinant
chimeric
particles
Prior art date
Application number
BRPI0417509-3A
Other languages
English (en)
Inventor
Ashley Birkett
Walter Fiers
Original Assignee
Apovia Inc
Vlaams Interuniv Inst Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/732,862 external-priority patent/US20040146524A1/en
Application filed by Apovia Inc, Vlaams Interuniv Inst Biotech filed Critical Apovia Inc
Publication of BRPI0417509A publication Critical patent/BRPI0417509A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

MOLéCULA DE PROTEìNA QUIMéRICA DE NúCLEO DE VìRUS DA HEPATITE B (HBC) RECOMBINANTE, PARTìCULAS, VACINA OU INóCULO, áCIDO NUCLEICO, MOLéCULA DE áCIDO NUCLEICO RECOMBINANTE, E, CéLULA HOSPEDEIRA Revela-se uma proteína de nucleocapsídeo do vírus da hepatite B (HBc) truncada carbóxi-terminal, quimérica, que contém um imunógeno para induzir a produção de anticorpos para a proteína M2 da influenza. Uma seqüência de influenza imunogênica, em de duas a quatro cópias, é expressa, de preferência, no N-terminal ou próximo da mesma, ou na seqüência de alça imunogênica da HBc. A quimera de HBc contém, de preferência, um epitopo de células T específico para influenza e é manipulado, de preferência para maior estabilidade de partículas auto-montadas, e também para maior rendimento dessas partículas quiméricas. Revela-se também métodos para preparar e usar as quimeras.
BRPI0417509-3A 2003-12-10 2004-12-09 molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira BRPI0417509A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/732,862 US20040146524A1 (en) 2002-02-21 2003-12-10 Stabilized immunogenic HBc chimer particles
US10/787,734 US7361352B2 (en) 2001-08-15 2004-02-26 Influenza immunogen and vaccine
PCT/US2004/041879 WO2005055957A2 (en) 2003-12-10 2004-12-09 Influenza immunogen and vaccine

Publications (1)

Publication Number Publication Date
BRPI0417509A true BRPI0417509A (pt) 2007-05-08

Family

ID=34681746

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417509-3A BRPI0417509A (pt) 2003-12-10 2004-12-09 molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira

Country Status (11)

Country Link
US (2) US7361352B2 (pt)
EP (2) EP1708748A4 (pt)
JP (1) JP2007513634A (pt)
KR (1) KR101209484B1 (pt)
CN (1) CN1913920B (pt)
AU (1) AU2004296886B2 (pt)
BR (1) BRPI0417509A (pt)
CA (1) CA2549104A1 (pt)
IL (1) IL200341A (pt)
NO (1) NO20063157L (pt)
WO (1) WO2005055957A2 (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7351413B2 (en) 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
KR100991679B1 (ko) * 2002-12-10 2010-11-04 셀덱스 테라퓨틱스 리미티드 안정화 면역원성 ＨＢｃ 키메라 입자
US20090162400A1 (en) * 2004-12-21 2009-06-25 Powell Thomas J Compositions of influenza viral proteins and methods of use thereof
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
TW200700079A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition
US20070160628A1 (en) * 2005-08-31 2007-07-12 Birkett Ashley J Stabilized virus-like particles and epitope display systems
ES2359214T5 (es) 2005-11-01 2014-10-08 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual por tratamiento con beta-propiolactona
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL1945252T3 (pl) 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
BRPI0618254A2 (pt) * 2005-11-04 2011-08-23 Novartis Vaccines & Diagnostic emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
EP3011969A1 (en) * 2006-03-07 2016-04-27 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
WO2007127290A2 (en) * 2006-04-24 2007-11-08 Protelix, Inc. Method for producing viral vaccine and therapeutic peptide antigens
JP2009543554A (ja) 2006-07-14 2009-12-10 サノフィ パスツール バイオロジクス カンパニー ベクターウイルスタンパク質への外来免疫決定基の直接トランスポゾン媒介挿入による組換え型ウイルスワクチンの構築
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
WO2008032219A2 (en) * 2006-09-11 2008-03-20 Novartis Ag Making influenza virus vaccines without using eggs
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8080645B2 (en) * 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
CA2664791A1 (en) 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co. Recombinant rhinovirus vectors
ZA200901993B (en) 2006-09-29 2010-07-28 Sanofi Pasteur Biologics Co Novel neutralizing immunogen (NIMIV) of rhinovirus and its use for vaccine applicants
AU2007317847B2 (en) 2006-11-07 2013-10-31 Sanofi Pasteur Biologics, Llc Stabilization of vaccines by lyophilization
CA2669485C (en) * 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2625460T5 (es) * 2006-12-15 2020-11-04 Boehringer Ingelheim Animal Health Usa Inc Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
US8741849B2 (en) * 2007-01-10 2014-06-03 Purdue Research Foundation Kinase inhibitors and uses thereof
EP2155228B1 (en) 2007-01-10 2014-04-02 Purdue Research Foundation Polypeptide inhibitors of hsp27 kinase and uses therefor
EP2117588A4 (en) * 2007-02-09 2011-05-04 Sanofi Pasteur Biologics Co VIRAL VECTORS AND METHODS OF USE
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
WO2008118487A2 (en) * 2007-03-26 2008-10-02 University Of Massachusetts Medical School Compositions and methods for incresing immunogenicity of glycoprotein vaccines
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
US20090196915A1 (en) * 2007-08-21 2009-08-06 Gary Van Nest Composition and methods of making and using influenza proteins
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CA2976814C (en) 2007-08-27 2022-12-13 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods for treating influenza
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2195466B1 (en) 2007-10-01 2012-10-10 Longhorn Vaccines & Diagnostics, LLC Method of storing biological specimens
WO2009079564A2 (en) * 2007-12-17 2009-06-25 Emory University Immunogenic compositions and methods of use thereof
BRPI0821456A2 (pt) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Partícula similar à pcv2 orf2 com inserção de aminoácido estranho
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110110973A1 (en) * 2008-02-09 2011-05-12 Sanofi Pasteur Biologics Co. Influenza B Vaccines
WO2009128952A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of papillomavirus proteins and methods of use
US8329188B2 (en) * 2008-11-12 2012-12-11 Theraclone Sciences, Inc. Human M2e peptide immunogens
EP2378875B1 (en) * 2008-12-10 2018-05-30 Purdue Research Foundation Cell-permeant peptide-based inhibitor of kinases
WO2010086743A2 (en) 2009-02-02 2010-08-05 Chrontech Pharma Ab Compositions and methods that enhance an immune response
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
BR112012000826B1 (pt) 2009-07-06 2022-07-26 Variation Biotechnologies Inc Método para a preparação de vesículas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
WO2011017132A2 (en) * 2009-07-27 2011-02-10 Purdue Research, Foundation Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
AU2011230491A1 (en) * 2010-03-26 2012-10-18 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza Matrix 2 protein, expression system, and uses thereof
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US20130323280A1 (en) 2011-01-13 2013-12-05 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
EA034702B1 (ru) * 2011-04-26 2020-03-10 Молекулар Экспресс, Инк. Липосомные композиции
CN103083656A (zh) * 2011-10-27 2013-05-08 苏州科贝生物技术有限公司 甲型流感病毒保守肽M2e与病毒样颗粒的缀合物及应用
CA2890084C (en) 2011-11-18 2021-05-04 Maura Ellen Campbell Synthetic derivatives of mpl and uses thereof
EP2802353A4 (en) 2012-01-12 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
EP2806890A4 (en) 2012-01-26 2015-09-02 Longhorn Vaccines & Diagnostics Llc COMPOSITIONAL ANTIGEN SEQUENCES AND VACCINES
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
WO2013134636A1 (en) 2012-03-09 2013-09-12 Purdue Research Foundation Compositions and methods for delivery of kinase inhibiting peptides
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
WO2014039661A1 (en) * 2012-09-05 2014-03-13 Stryker Corporation Patient support
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
WO2014074509A1 (en) * 2012-11-07 2014-05-15 Vacplanta Limted Production of an immunogen using a plant virus
DK3052516T3 (da) 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN113164445A (zh) 2018-08-02 2021-07-23 得克萨斯系统大学评议会 Tlr1/2激动剂地普罗考姆的佐剂作用协同增效检查点抑制性抗体以消除疾病
US20220356538A1 (en) * 2019-09-24 2022-11-10 The Penn State Research Foundation Hepatitis b virus mutants with increased covalently closed circular dna
US12485166B2 (en) 2020-02-06 2025-12-02 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections
EP4103283A4 (en) 2020-03-26 2024-02-28 Provectus Pharmatech, Inc. NEW USES OF HALOGENATED XANTHENES IN ONCOLOGY AND VIROLOGY
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
WO2022087122A1 (en) 2020-10-20 2022-04-28 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
WO2022187132A1 (en) * 2021-03-04 2022-09-09 Longhorn Vaccines And Diagnostics, Llc Vaccines for the treatment and prevention of zoonotic infections

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US4888170A (en) 1981-10-22 1989-12-19 Research Corporation Vaccines obtained from antigenic gene products of recombinant genes
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4977092A (en) * 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4539205A (en) 1982-11-09 1985-09-03 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4643992A (en) 1982-11-09 1987-02-17 Scripps Clinic And Research Foundation Modulation of animal cellular responses with compositions containing 8-substituted guanine derivatives
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US5093318A (en) 1983-11-01 1992-03-03 Scripps Clinic And Research Foundation Immunostimulating guanosine derivatives and their pharmaceutical compositions
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US4818527A (en) * 1986-12-09 1989-04-04 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
US4976958A (en) * 1987-02-26 1990-12-11 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
JPH04501801A (ja) 1988-09-06 1992-04-02 ワシントン ユニバーシティ トランスジェニック植物による経口的免疫化
US5023179A (en) 1988-11-14 1991-06-11 Eric Lam Promoter enhancer element for gene expression in plant roots
US5110732A (en) 1989-03-14 1992-05-05 The Rockefeller University Selective gene expression in plants
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5618988A (en) 1990-03-02 1997-04-08 Amoco Corporation Enhanced carotenoid accumulation in storage organs of genetically engineered plants
CA2055447C (en) 1990-03-02 2006-12-19 Rodney Lee Ausich Biosynthesis of carotenoids in genetically engineered hosts
US5057588A (en) 1990-03-09 1991-10-15 Hoechst Celanese Corp. Vinylidene cyanide alternating copolymers
US5709879A (en) 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5297441A (en) 1992-08-14 1994-03-29 The Boeing Company Apparatus for supporting a test specimen for compression testing
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
JP3701761B2 (ja) * 1997-01-08 2005-10-05 本田技研工業株式会社 車両用シート
US6355257B1 (en) 1997-05-08 2002-03-12 Corixa Corporation Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US7063967B2 (en) 1997-05-08 2006-06-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
BR9809149A (pt) 1997-05-20 2000-08-01 Galenica Pharmaceuticals Inc Análogos de triterpeno saponina dotados de adjuvante e atividade imonoestimulatória
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DE69832706T2 (de) * 1997-08-05 2006-08-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Immunschützendes influenzaantigen und dessen verwendung zur impfung
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US6024961A (en) 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
CA2314934C (en) 1997-12-16 2006-08-29 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
NZ506245A (en) 1998-02-12 2003-08-29 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US5990085A (en) * 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
AU770225B2 (en) 1998-12-04 2004-02-19 Biogen Idec Ma Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
ATE324448T1 (de) 1999-10-08 2006-05-15 Celltech Pharma Europ Ltd Design von immunogene
WO2001041759A1 (en) 1999-12-10 2001-06-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulation of oocyte activation
ES2260235T3 (es) 2000-06-22 2006-11-01 Ucb Pharma Limited Modificacion del antigeno "core" de la hepatitis b.
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
US20030198645A1 (en) * 2002-02-21 2003-10-23 Mark Page Stabilized HBc chimer particles as therapeutic vaccine for chronic hepatitis

Also Published As

Publication number Publication date
WO2005055957A3 (en) 2005-11-03
NO20063157L (no) 2006-09-11
AU2004296886A1 (en) 2005-06-23
IL200341A (en) 2013-01-31
US7361352B2 (en) 2008-04-22
EP1708748A2 (en) 2006-10-11
US8017127B2 (en) 2011-09-13
EP1708748A4 (en) 2008-03-19
JP2007513634A (ja) 2007-05-31
CN1913920B (zh) 2013-03-27
US20060115489A1 (en) 2006-06-01
EP2425848A3 (en) 2012-06-20
KR20070008535A (ko) 2007-01-17
CN1913920A (zh) 2007-02-14
EP2425848A2 (en) 2012-03-07
AU2004296886B2 (en) 2008-10-02
WO2005055957A2 (en) 2005-06-23
KR101209484B1 (ko) 2012-12-07
CA2549104A1 (en) 2005-06-23
US20070036826A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
BRPI0417509A (pt) molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira
RU2011128371A (ru) Модифицированные f протеины sv и способы их применения
Lua et al. Bioengineering virus‐like particles as vaccines
Arora et al. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
Xu et al. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine
Schumacher et al. Enhanced stability of a chimeric hepatitis B core antigen virus-like-particle (HBcAg-VLP) by a C-terminal linker-hexahistidine-peptide
RU2014101401A (ru) Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
BRPI0416393A (pt) molécula de ácido nucleico, vetor, célula hospedeira, partìculas semelhantes a vìrus, métodos para produzir as mesmas, para prevenir infecção por hpv, e para induzir uma resposta imune em um animal, vacina, composições farmacêuticas, e, polipeptìdeo hpv58 l1 isolado e purificado
RU2014142785A (ru) Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
JP2009268467A5 (pt)
BRPI0614761A2 (pt) proteìnas de fusão de albumina
CA2413546A1 (en) Modification of hepatitis b core antigen
EA201170217A1 (ru) Гибридные полипептидные антигены респираторно-синцитиального вируса
MXPA05008677A (es) Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica.
AR045804A1 (es) Expresion optimizada de l1 del vph45 en levaduras
RU2014135703A (ru) Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2, h2n2 и b
JP2010532656A5 (pt)
WO2008034388A8 (en) Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof
JP2012516140A5 (pt)
Akhras et al. Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response
Jafari et al. Designing a chimeric subunit vaccine for influenza virus, based on HA2, M2e and CTxB: a bioinformatics study
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
WO2005021713A3 (en) Vectors expressing sars immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using
CN114364692A (zh) 嵌合的乳头瘤病毒l1蛋白
CA2509484A1 (en) Stabilized immunogenic hbc chimer particles

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2283 DE 07/10/2014.